Allergy medications that are not anticholinergic offer a safer, better-tolerated approach to managing conditions such as hay fever, urticaria, and allergic rhinitis — particularly for those requiring long-term treatment. Older, first-generation antihistamines like chlorphenamine and promethazine carry a significant anticholinergic burden, linked to side effects including dry mouth, urinary retention, sedation, and cognitive impairment. Second-generation antihistamines and other non-anticholinergic options have been developed to address these concerns. This article outlines the available choices, explains who benefits most from avoiding anticholinergic medicines, and provides guidance aligned with NHS, NICE, and MHRA recommendations.

Why Anticholinergic Effects Matter When Treating Allergies

First-generation antihistamines carry significant anticholinergic burden, causing side effects such as dry mouth, urinary retention, sedation, and cognitive impairment; NICE KTT26 provides UK guidance on minimising this risk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Anticholinergic drugs work by blocking muscarinic acetylcholine receptors throughout the body. Whilst this mechanism can be therapeutically useful in some conditions, it produces a well-recognised cluster of side effects that can significantly affect quality of life and, in certain populations, patient safety. These effects include dry mouth, blurred vision, urinary retention, constipation, tachycardia, and cognitive impairment.

In the context of allergy treatment, the concern is particularly relevant because older, first-generation antihistamines — such as chlorphenamine and promethazine — carry substantial anticholinergic burden. Regular or long-term use of these medicines has been associated with sedation, impaired driving ability, and reduced cognitive performance. Some research, including studies published in journals such as JAMA Internal Medicine, has raised questions about whether cumulative anticholinergic exposure over many years may be associated with an increased risk of dementia. However, this remains an area of ongoing investigation; association does not prove causation, and no definitive causal link has been established. NICE Key Therapeutic Topic KTT26 (Anticholinergic burden) provides UK-focused guidance on assessing and minimising this risk.

For people who require allergy treatment on a frequent or long-term basis — for example, those managing perennial allergic rhinitis or chronic urticaria — minimising anticholinergic exposure is a clinically meaningful goal. Understanding which allergy medicines carry low or negligible anticholinergic activity allows patients and clinicians to make more informed, safer prescribing decisions. This is especially important given that many allergy medicines are available over the counter, meaning patients may self-select treatments without professional guidance.

Antihistamines With Low or No Anticholinergic Activity

Second-generation antihistamines — including cetirizine, loratadine, fexofenadine, bilastine, and desloratadine — are considered to have low or negligible anticholinergic activity and are the preferred first-line choice for most allergic conditions.

Second-generation antihistamines are widely regarded as the preferred first-line option for most allergic conditions, largely because they have been specifically developed to minimise anticholinergic and sedative effects. They achieve this through greater selectivity for peripheral H1 receptors and reduced penetration of the blood-brain barrier compared with their first-generation predecessors.

The following second-generation antihistamines are commonly used in the UK and are considered to have low or negligible anticholinergic activity:

• Cetirizine — widely available over the counter; effective for hay fever, urticaria, and perennial rhinitis. Mildly sedating in a minority of individuals but with minimal anticholinergic burden.

• Loratadine — non-sedating in most patients; a good option where alertness is a priority, such as for drivers or those operating machinery.

• Fexofenadine — considered one of the least sedating options and does not readily cross the blood-brain barrier. In the UK, fexofenadine 120 mg is available over the counter for seasonal allergic rhinitis (hay fever) in adults and young people aged 12 and over; fexofenadine 180 mg is a prescription-only medicine (POM) licensed for chronic idiopathic urticaria. Higher-dose regimens sometimes used in chronic spontaneous urticaria are off-label and should be directed by a specialist.

• Bilastine — a newer second-generation antihistamine available on prescription in the UK; non-sedating and with a favourable tolerability profile. It should be taken on an empty stomach, as food and fruit juices (including grapefruit juice) can reduce absorption — patients should follow the instructions in their patient information leaflet.

• Desloratadine — the active metabolite of loratadine; available on prescription and similarly free from significant anticholinergic effects.

It is worth noting that even within second-generation antihistamines, individual responses can vary. Cetirizine, for instance, causes drowsiness in a minority of users. Patients should be advised to assess their own response before driving or undertaking tasks requiring concentration. The MHRA and product manufacturers provide specific guidance on this within patient information leaflets (available via the Electronic Medicines Compendium, emc.medicines.org.uk).

Not sure if this is normal? Chat with one of our pharmacists →

Other Allergy Treatments That Avoid Anticholinergic Side Effects

Intranasal corticosteroids, sodium cromoglicate, azelastine nasal spray, montelukast, and allergen immunotherapy all carry no meaningful anticholinergic activity and are suitable alternatives or adjuncts to oral antihistamines.

Beyond antihistamines, several other allergy treatments are available that carry no meaningful anticholinergic activity, making them suitable alternatives or adjuncts — particularly for patients who require more comprehensive symptom control or who cannot tolerate antihistamines.

Intranasal corticosteroids are considered the most effective treatment for moderate-to-severe allergic rhinitis according to NICE CKS guidance on allergic rhinitis. Preparations such as fluticasone propionate, mometasone furoate, and beclometasone dipropionate act locally within the nasal mucosa to reduce inflammation. Systemic absorption is minimal at recommended doses, and they carry no anticholinergic effects. They are available both over the counter and on prescription.

Intranasal antihistamines — such as azelastine nasal spray, or the combined azelastine/fluticasone propionate nasal spray — are additional non-anticholinergic options for allergic rhinitis available in the UK. They act locally and are not associated with the systemic anticholinergic effects seen with oral first-generation antihistamines.

Sodium cromoglicate is a mast cell stabiliser available as eye drops and nasal spray. It prevents the release of histamine and other inflammatory mediators and has no anticholinergic properties. It is particularly useful for allergic conjunctivitis and mild rhinitis, though it requires regular dosing (typically four times daily) to be effective.

Montelukast, a leukotriene receptor antagonist available on prescription, is sometimes used as an add-on therapy for allergic rhinitis and asthma. It has no anticholinergic activity. However, the MHRA issued updated guidance in 2019 highlighting neuropsychiatric side effects — including sleep disturbances, nightmares, anxiety, and mood changes — that must be discussed with patients before prescribing. If such symptoms develop, patients should stop montelukast, seek medical advice promptly, and report the reaction via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Allergen immunotherapy (desensitisation), available through specialist NHS allergy services, addresses the underlying immune response rather than simply managing symptoms. It carries no anticholinergic burden and may offer long-term benefit for selected patients with severe allergic rhinitis or venom allergy, in line with BSACI guidance on allergen immunotherapy.

Who Should Prioritise Non-Anticholinergic Allergy Medicines

Older adults, people with cognitive impairment, those with urinary conditions, drivers, and pregnant or breastfeeding women should prioritise non-anticholinergic allergy medicines to minimise risk of harm.

Whilst minimising anticholinergic exposure is broadly sensible for all patients requiring regular allergy treatment, certain groups have a particularly strong clinical rationale for avoiding medicines with anticholinergic activity.

Older adults are among the most vulnerable. Age-related changes in pharmacokinetics — including reduced renal clearance and altered blood-brain barrier permeability — mean that anticholinergic drugs accumulate more readily and exert greater central nervous system effects. NICE KTT26 and NHS guidance both highlight the risks of polypharmacy and anticholinergic burden in older patients. Tools such as the Anticholinergic Cognitive Burden (ACB) scale are used clinically to help assess cumulative risk; however, it is important to note that the ACB is one of several available tools (others include the Anticholinergic Risk Scale and the Drug Burden Index) and none is nationally mandated. These tools should support, not replace, clinical judgement. First-generation antihistamines such as promethazine and chlorphenamine score highly on such scales and should generally be avoided in older adults. The BNF also highlights specific cautions for antihistamine use in the elderly.

People with cognitive impairment or dementia should avoid anticholinergic medicines wherever possible, as these drugs can worsen confusion, agitation, and memory difficulties.

Individuals with urinary conditions, including benign prostatic hyperplasia or overactive bladder, may find that anticholinergic antihistamines exacerbate urinary retention or hesitancy.

Drivers and those in safety-critical occupations should be advised to use non-sedating, low-anticholinergic options such as loratadine or fexofenadine, as sedating antihistamines can impair reaction times and concentration — with legal implications under UK road traffic law and DVLA fitness-to-drive guidance.

Pregnant and breastfeeding women should seek pharmacist or GP advice before using any antihistamine. Based on available UK safety data — including guidance from the Specialist Pharmacy Service (SPS) and the UK Teratology Information Service (UKTIS) — loratadine and cetirizine are generally considered the preferred oral antihistamine options during pregnancy. All medicines should be used at the lowest effective dose for the shortest necessary duration, and professional advice should always be sought.

Choosing the Right Allergy Treatment: NHS and NICE Guidance

NICE CKS recommends second-generation antihistamines as first-line for mild allergic rhinitis and intranasal corticosteroids for moderate-to-severe symptoms; first-generation antihistamines are not recommended for routine use.

NICE CKS guidance on allergic rhinitis recommends a stepwise approach to management, with treatment selection based on symptom severity, frequency, and patient preference. For mild, intermittent symptoms, an oral second-generation antihistamine such as cetirizine or loratadine is appropriate as first-line therapy. For moderate-to-severe or persistent symptoms, an intranasal corticosteroid is recommended, either alone or in combination with an antihistamine.

NICE and NHS guidance consistently favour second-generation antihistamines over first-generation options for routine allergy management, citing their improved tolerability and safety profile. First-generation antihistamines are not recommended for regular use in adults or children due to their sedating and anticholinergic properties. The British Society for Allergy and Clinical Immunology (BSACI) similarly endorses this approach in its published guidelines.

For allergic conjunctivitis, topical sodium cromoglicate or antihistamine eye drops are preferred, as they act locally and avoid systemic anticholinergic exposure. UK-available options include ketotifen (available over the counter) and olopatadine (available on prescription), in line with NICE CKS guidance on allergic conjunctivitis.

For chronic spontaneous urticaria (CSU), NICE CKS and BSACI guidance recommend non-sedating antihistamines as first-line treatment. Dose escalation of non-sedating antihistamines beyond the standard licensed dose is sometimes used in CSU but is off-label; this should be undertaken only under specialist supervision. Patients with inadequately controlled symptoms should be referred to a specialist.

When selecting between available second-generation antihistamines, practical considerations include:

• Dosing frequency: fexofenadine and loratadine are once-daily; cetirizine is also once-daily but may cause mild sedation in some individuals.

• Cost and availability: cetirizine and loratadine are inexpensive and widely available over the counter.

• UK licensing: fexofenadine 120 mg is available over the counter for hay fever; 180 mg is prescription-only for urticaria.

• Individual response: patients may respond better to one agent than another, and a trial-and-switch approach is reasonable.

When to Speak to a GP or Pharmacist About Your Options

Seek emergency help for signs of anaphylaxis; consult a pharmacist if unsure about interactions or suitability, and see a GP if symptoms are poorly controlled, side effects occur, or a prescription-only option is needed.

Many allergy medicines are available without a prescription in the UK, which makes them convenient but also means patients may use them without professional oversight. Whilst second-generation antihistamines and intranasal corticosteroids are generally safe for short-term self-management, there are several circumstances in which seeking advice from a GP or pharmacist is strongly recommended.

Seek emergency help immediately (call 999) if you experience:

• Difficulty breathing, wheezing, or throat tightening

• Swelling of the tongue, lips, or throat

• Dizziness, collapse, or loss of consciousness These may be signs of anaphylaxis, which is a medical emergency.

Seek urgent same-day assessment if you experience:

• Eye pain, sensitivity to light (photophobia), or sudden changes in vision These symptoms require prompt clinical assessment to exclude serious eye conditions.

Speak to a pharmacist if:

• You are unsure which antihistamine is most appropriate for your symptoms.

• You are taking other regular medicines and want to check for interactions.

• You are pregnant, breastfeeding, or managing a child's allergy symptoms.

• Symptoms are not adequately controlled after two weeks of over-the-counter treatment.

Speak to a GP if:

• Allergy symptoms are significantly affecting your sleep, work, or daily activities.

• You have been using first-generation antihistamines regularly and wish to switch to a safer alternative.

• You are an older adult or have cognitive concerns and want a review of your current medicines for anticholinergic burden.

• You experience side effects such as urinary difficulties, confusion, or palpitations after taking an antihistamine.

• You require a prescription-only option such as fexofenadine 180 mg, bilastine, or montelukast.

• You are interested in allergen immunotherapy as a longer-term solution.

If you suspect you have experienced a side effect from any allergy medicine, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This applies to both prescription and over-the-counter medicines.

It is also worth noting that persistent or worsening nasal symptoms — particularly if one-sided, associated with nosebleeds, or accompanied by facial pain — should always be assessed by a clinician to exclude non-allergic causes. Regular medication reviews, particularly in older adults, are an important opportunity to reassess anticholinergic burden and optimise allergy management safely.

Frequently Asked Questions